A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus

NCT03170518 PHASE3 COMPLETED Results posted

The purpose of this study is to assess the effect of canagliflozin relative to placebo on glycated hemoglobin (HbA1c) after 26 weeks of treatment, and to assess the overall safety and tolerability of canagliflozin.

Details

Lead sponsor	Janssen Research & Development, LLC
Phase	PHASE3
Status	COMPLETED
Enrolment	171
Start date	Fri Jul 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Sep 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Diabetes Mellitus, Type 2

Interventions

• Canagliflozin 100 mg
• Canagliflozin 300 mg
• Placebo

Countries

Russia, Greece, Malaysia, Poland, Mexico, Philippines, China, United States, Brazil, India